Spectral AI, Inc. (formerly Spectral MD, Inc.)

Dallas, Texas, United States All United States companies → — Founded 2009

Medical Device / Hardware Point-of-Care Diagnostics Specialty-Focused AI

Dermatology Emergency Medicine Plastic Surgery

Clinical Decision Support & Reference Dermatology AI Radiology & Imaging AI

Public (Nasdaq: MDAI) — More than $250 million in non-dilutive government funding since 2013, including a BARDA contract valued up to $150 million with $86 million committed to date. Additionally, the company secured up to $15 million in debt financing and $2.7 million in equity financing in March 2025.

Claim this company

Products

DeepView AI System

Spectral AI, Inc. (formerly Spectral MD, Inc.)

Clinical Decision Support & Reference

DeepView AI System is an AI-based wound assessment and imaging platform that uses advanced multispectral imaging and deep learning to deliver objective predictions of wound healing potential for burn wounds.

See all 1 product →

About Spectral AI, Inc. (formerly Spectral MD, Inc.)

Spectral AI, Inc. (formerly Spectral MD, Inc.) is a Dallas-based healthcare AI company specializing in predictive medical diagnostics for wound care. Their flagship product, the DeepView® System, utilizes proprietary AI algorithms combined with multispectral imaging to provide an objective and immediate assessment of a wound’s healing potential. This technology aims to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics that are invisible to the naked eye at the initial presentation of a wound. The DeepView System delivers a binary prediction on whether a wound will heal by a specified time point, assisting physicians in making more accurate, timely, and informed treatment decisions.

The company’s primary focus is on burn indications, an area where early and accurate assessment significantly impacts treatment choices and patient outcomes. The DeepView System has received De Novo Classification by the U.S. Food and Drug Administration (FDA) in May 2026, authorizing U.S. commercial sales, and also obtained initial UKCA (UK Conformity Assessed) authorization in the United Kingdom in February 2024. Spectral AI has also secured substantial non-dilutive government funding, including a significant contract with the Biomedical Advanced Research and Development Authority (BARDA), to support the development and commercialization of its DeepView System.

Focus Areas

medical diagnostics predictive analytics wound care burn assessment diabetic foot ulcers AI multispectral imaging

Business Intelligence

Key Investors	Vanguard Capital Management Llc, Highlander Partners, L.P., Marshall Wace, Llp, Bridgeway Capital Management Inc, Jane Street Group, Llc, UBS Group AG, Geode Capital Management, Llc, Hudson Bay Capital Management LP, Avantax Planning Partners Inc, Renaissance Technologies LLC, Rathbones Group PLC
Partnerships	Royal College of Surgeons in Ireland, BARDA (Biomedical Advanced Research and Development Authority)
Acquisitions	Rosecliff Acquisition I (merged with)
Technology	DeepView System combines multispectral imaging with proprietary AI algorithms for wound healing prediction. It is non-invasive, non-radiation, and non-laser, not requiring injectable dye.
FDA Clearances	1 cleared products (estimated)

What Physicians Need to Know

Specialization

Spectral AI specializes in predictive medical diagnostics, particularly in wound care for burns and diabetic foot ulcers (DFUs). They focus on providing 'Day One' healing predictions to guide treatment decisions.

Key Differentiators

Their DeepViewu00ae System combines AI and multispectral imaging to assess wound healing potential, offering objective and immediate assessments that are not visible to the human eye. The system has shown superior accuracy compared to unaided clinical judgment in burn wound assessment. It also accounts for melanin, providing objective assessments regardless of skin tone.

Technology Stack

The core technology is the DeepViewu00ae Wound Imaging System, a portable multimodal imaging platform. It utilizes proprietary multispectral optics and sensors to capture images across various wavelengths, from visible blue to deep infrared, to analyze tissue physiology and viability biomarkers like hemoglobin oxygenation and tissue hydration. These multispectral data points are integrated with patient clinical data into AI algorithms for wound healing prediction.

Burn Assessment

The DeepViewu00ae System provides a 'Day One' wound healing assessment for burns, with 92% accuracy in predicting if a burn wound will heal or not. This helps clinicians determine the need for surgical intervention sooner, moving away from a 'wait-and-see' approach.

Diabetic Foot Ulcers

For DFUs, the DeepViewu00ae technology provides 86% accuracy in predicting if a DFU will close 50% of its area by week 4. This aims to reduce the reliance on subjective assessments and enable earlier advanced wound care therapies, potentially preventing amputations.

AI and Predictive Analytics

Spectral AI's predictive AI algorithms distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye. The company owns the largest burn biopsy tissue bank and extensive burn and DFU image databases, which are used to train and improve their AI models.

Regulatory Status & Funding

The DeepViewu00ae System for Burn Indication received De Novo Classification from the U.S. FDA in May 2026, allowing for U.S. commercialization. It also received initial UKCA authorization in the United Kingdom in February 2024. The company has secured over $130 million in U.S. Government contracts, including from BARDA, to support its technology development.

Physician Tip

For physicians, Spectral AI's DeepViewu00ae System offers objective, immediate, and highly accurate wound healing predictions for burns and diabetic foot ulcers, directly at the point of care. This can significantly improve triage, treatment planning, and patient outcomes by enabling earlier interventions and reducing the 'wait-and-see' period. The non-contact and fast image acquisition (0.2 seconds for acquisition, 20-25 seconds for AI processing) makes it practical for real-world clinical settings. The system's ability to 'see the unknown' below the skin surface provides crucial information that traditional visual assessments miss, leading to more informed decisions and potentially reducing healthcare costs.

Spectral AI is working on EHR interoperability and clinical documentation workflows. Their clinical application pipeline includes future opportunities for AI-3D wound measurement, AI-Venous Leg Ulcer (VLU) indication, AI-Critical Limb Ischemia (CLI) indication, AI-Digital Health, AI-Guided Therapy, and AI-Cosmetics, leveraging their universal imaging platform.

At a glance

Founded 2009

HQ Dallas, Texas, United States · United States

Team size 65

CEO Vince Capone

Funding Public (Nasdaq: MDAI) — More than $250 million in non-dilutive government funding since 2013, including a BARDA contract valued up to $150 million with $86 million committed to date. Additionally, the company secured up to $15 million in debt financing and $2.7 million in equity financing in March 2025.

FDA clearances 1 (estimated)

Products 1

Products by Spectral AI, Inc. (formerly Spectral MD, Inc.)

1 product in the directory

DeepView AI System

Spectral AI, Inc. (formerly Spectral MD, Inc.)

Clinical Decision Support & Reference

What the Web Says

Spectral AI, Inc., formerly Spectral MD, Inc., is generally viewed as a company with promising technology, particularly its AI-driven wound imaging system, DeepView, which aims to improve diagnostic accuracy and patient outcomes. However, as an employer, there are mixed reviews regarding work-life balance and management, with some employees praising the mission and team while others express concerns about workload and internal communication.

Overall: Mixed

Strengths

Innovative and promising AI technology for wound assessment (DeepView)
Potential to significantly improve healthcare diagnostics and patient care
Strong company mission and vision
Dedicated and intelligent colleagues
Positive impact on medical field
Good benefits for employees

Limitations

Work-life balance can be challenging due to demanding workload
Some concerns about management effectiveness and communication
Startup environment can lead to rapid changes and uncertainty
Limited public reviews on major platforms like G2, Capterra specific to product
Potential for high-pressure environment
Compensation could be more competitive for some roles

Based on reviews from: Glassdoor, Reddit, Healthcare IT News (mentions/articles), Company press releases/investor relations (for product focus)

Last updated: 2026-09-23

Videos

News, demos, and interviews about Spectral AI, Inc. (formerly Spectral MD, Inc.).

Loading videos...

Videos load interactively. If none appear, search YouTube for Spectral AI, Inc. (formerly Spectral MD, Inc.) →

View all on YouTube

Press & Coverage

Spectral AI, Inc. (GlobeNewswire)

Spectral AI Awarded $31.7 Million of BARDA Funding to Accelerate Development of the DeepViewu00ae System

Spectral AI, Inc. received $31.7 million in funding from BARDA to accelerate the development of its DeepViewu00ae System, an AI-driven burn wound imaging technology. This non-dilutive funding is in addition to $54.9 million already committed, as the company awaits FDA market authorization.

2026-03

Spectral AI, Inc. (GlobeNewswire)

Spectral AI Receives FDA De Novo Clearance for DeepViewu00ae System for Burn Indication

Spectral AI, Inc. announced that the U.S. Food and Drug Administration (FDA) granted De Novo Classification for its DeepViewu00ae System, authorizing commercial distribution in the United States for burn care. This marks a significant milestone for the company's innovative predictive medical technology.

2026-05

GlobeNewswire

Spectral AI Names Darcy Bajko Chief Commercial Officer to Lead Global Sales Launch of FDA-Cleared DeepViewu00ae System for Burn Indication

Spectral AI, Inc. appointed Darcy Bajko as Chief Commercial Officer to lead the global sales launch of its DeepViewu00ae System for burn indication, following its FDA De Novo Classification in May 2026. Her role will focus on building a sales and marketing organization and driving clinical adoption.

2026-07

GlobeNewswire

Spectral AI to Present at H.C. Wainwright 28th Annual Global Investment Conference

Spectral AI, Inc. announced that its CEO and CFO are scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference, highlighting the company's growth strategy and readiness for the 2026 commercial launch of its FDA-cleared DeepViewu00ae System.

2026-09

Nasdaq (RTTNews)

Spectral AI Highlights DeepView System For Burn Indication Ahead

Spectral AI, Inc. showcased its FDA-cleared DeepView System for Burn Indication and featured presentations by burn care executives. The company is focused on medical diagnostics using AI for faster and more accurate treatment decisions.

2026-09

MedTech Dive

Spectral AI algorithms beat physicians in burn tissue assessments

Spectral AI's DeepView System demonstrated superior performance over burn physicians in identifying non-healing tissue, achieving 86.6% sensitivity compared to 40.8% for clinical judgment. The company plans to file these results with the FDA by mid-2025 and launch the product in 2026.

2025-03

Nasdaq (GlobeNewswire)

Spectral AI Raises up to $15 Million of Debt Financing and Strengthens Financial Position for U.S. Commercialization

Spectral AI, Inc. secured up to $15.0 million in debt financing from Avenue Venture Opportunities Fund II, L.P., with an initial draw of $8.5 million, to accelerate its product commercialization efforts, including the upcoming U.S. launch of its DeepView System.

2025-03

Journal of Burn Care & Research (PMC)

Clinical Investigation of a Rapid Non-invasive Multispectral Imaging Device Utilizing an Artificial Intelligence Algorithm for Improved Burn Assessment

This clinical investigation details a rapid non-invasive multispectral imaging device utilizing an AI algorithm for improved burn assessment, with studies indicating 86% sensitivity and 79% specificity, outperforming attending physicians in partial-thickness burn analysis.

2023-07

Frequently Asked Questions

What is Spectral AI's core technology and how does it improve wound care diagnostics?

Spectral AI's core technology is the DeepViewu00ae System, which combines AI and multispectral imaging to provide immediate, objective predictions of wound healing potential. This non-invasive device captures physiological information not visible to the human eye, enabling faster and more accurate treatment decisions for conditions like burns and diabetic foot ulcers.

How accurate is the DeepViewu00ae System in assessing burn wounds compared to traditional clinical judgment?

The DeepViewu00ae System has demonstrated superior accuracy in identifying non-healing burn tissue compared to burn physicians' clinical judgment. In studies, DeepView achieved 86.6% sensitivity in identifying non-healing tissue at an image-wise level, while clinical judgment scored 40.8%.

What specific wound types can Spectral AI's technology assess, and are there plans for future applications?

Currently, Spectral AI's DeepViewu00ae System is cleared for burn assessment and is being developed for diabetic foot ulcers (DFUs). The company plans to expand its AI platform to include other indications such as AI-3D wound measurement, venous leg ulcers (VLUs), and critical limb ischemia (CLI).

What is the regulatory status of Spectral AI's products, particularly in the US and UK?

Spectral AI's DeepViewu00ae System received FDA De Novo Classification in May 2026, authorizing its commercial distribution in the United States for burn care. It also received initial UKCA (UK Conformity Assessed) authorization in the United Kingdom in February 2024.

What kind of support and training does Spectral AI offer to healthcare providers for implementing their technology?

Spectral AI offers support for implementing standardized assessment protocols, clinician training, and patient education programs. They also provide technical program support for optics and sensor integration, electronic hardware design, and clinical pathway implementation.

How does Spectral AI ensure data security and HIPAA compliance for patient information collected by the DeepViewu00ae System?

While specific details on DeepView's data security were not extensively detailed, Spectral AI emphasizes its focus on AI governance in healthcare, aiming for 90-95% visibility into AI usage to enforce policy at runtime and detect PHI exposure and policy violations within minutes.

What is the company's financial stability and market position?

Spectral AI, Inc. (MDAI) is a publicly traded company on NASDAQ. As of September 23, 2026, its shares were valued at $1.67 with a market cap of $53.59 million. The company has received over $130 million in U.S. Government contracts to support its technology development.

Related Companies

Suggest an Edit →